{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T14:25:21Z","timestamp":1776954321472,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.euo.2025.03.009","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T03:20:20Z","timestamp":1743477620000},"page":"1237-1247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Predictive Factors for Oligometastatic Renal Cell Carcinoma Treated with Stereotactic Radiation: A Retrospective Study"],"prefix":"10.1016","volume":"8","author":[{"given":"Allen","family":"Yen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alana","family":"Christie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihailo","family":"Miljanic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tidie","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurelie","family":"Garant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chul","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Timmerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Brugarolas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquibul","family":"Hannan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.03.009_b0005","unstructured":"Atkins MB, Bakouny Z, Choueiri TK. Epidemiology, pathology, and pathogenesis of renal cell carcinoma. In: Richie JP, editor. Waltham, MA: UpToDate."},{"key":"10.1016\/j.euo.2025.03.009_b0010","first-page":"339","article-title":"Current management options in metastatic renal cell cancer","volume":"11","author":"Gangadaran","year":"2017","journal-title":"Oncol Rev"},{"key":"10.1016\/j.euo.2025.03.009_b0015","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.03.009_b0020","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa2212851","article-title":"Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma","volume":"388","author":"Choueiri","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.03.009_b0025","doi-asserted-by":"crossref","first-page":"8491","DOI":"10.18632\/oncotarget.3455","article-title":"The biology and treatment of oligometastatic cancer","volume":"6","author":"Reyes","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.euo.2025.03.009_b0030","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.euo.2025.03.009_b0035","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2020.38.6_suppl.10","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): five-year results of a randomized phase II trial","volume":"38","author":"Ost","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.03.009_b0040","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non\u2013small-cell lung cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2025.03.009_b0045","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx015","article-title":"Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial","volume":"109","author":"Ruers","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euo.2025.03.009_b0050","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non\u2013small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.03.009_b0055","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.03.009_b0060","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2217\/fon.14.40","article-title":"Extracranial oligometastatic renal cell carcinoma: current management and future directions","volume":"10","author":"Loh","year":"2014","journal-title":"Future Oncol"},{"key":"10.1016\/j.euo.2025.03.009_b0065","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.radonc.2005.03.022","article-title":"Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma","volume":"77","author":"Wers\u00e4ll","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.euo.2025.03.009_b0070","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1080\/02841860600954875","article-title":"A prospective phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma","volume":"45","author":"Svedman","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1016\/j.euo.2025.03.009_b0075","unstructured":"National Comprehensive Cancer Network. Kidney cancer (version 4.2023). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf."},{"key":"10.1016\/j.euo.2025.03.009_b0080","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1016\/S1470-2045(14)70235-9","article-title":"Local treatments for metastases of renal cell carcinoma: a systematic review","volume":"15","author":"Dabestani","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.03.009_b0085","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S1470-2045(21)00528-3","article-title":"Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial","volume":"22","author":"Tang","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.03.009_b0090","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.euo.2021.12.001","article-title":"Phase II trial of stereotactic ablative radiation for oligoprogressive metastatic kidney cancer","volume":"5","author":"Hannan","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.03.009_b0095","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S1470-2045(20)30537-4","article-title":"Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study","volume":"22","author":"Chalkidou","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.03.009_b0100","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.ijrobp.2011.02.040","article-title":"Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma","volume":"82","author":"Zelefsky","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euo.2025.03.009_b0105","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijrobp.2019.07.023","article-title":"Stereotactic ablative radiation therapy (SAbR) used to defer systemic therapy in oligometastatic renal cell cancer","volume":"105","author":"Zhang","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euo.2025.03.009_b0110","unstructured":"Tang S, Wang K, Hein D, Lin G, Sanford NN, Wang J. Recurrence-free survival prediction for anal squamous cell carcinoma chemoradiotherapy using planning CT-based radiomics model. September 01, 2023. https:\/\/ui.adsabs.harvard.edu\/abs\/2023arXiv230902562T."},{"key":"10.1016\/j.euo.2025.03.009_b0150","series-title":"Logistic regression using the SAS system: theory and application","author":"Allison","year":"1999"},{"key":"10.1016\/j.euo.2025.03.009_b0115","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1088\/1361-6560\/aa6ae5","article-title":"Multi-objective radiomics model for predicting distant failure in lung SBRT","volume":"62","author":"Zhou","year":"2017","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.euo.2025.03.009_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110368","article-title":"PET\/CT based transformer model for multi-outcome prediction in oropharyngeal cancer","volume":"197","author":"Ma","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.euo.2025.03.009_b0125","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.euo.2022.06.008","article-title":"Stereotactic ablative radiation for systemic therapy-na\u00efve oligometastatic kidney cancer","volume":"5","author":"Hannan","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"6_suppl","key":"10.1016\/j.euo.2025.03.009_b0130","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1200\/JCO.2021.39.6_suppl.311","article-title":"Phase II trial of stereotactic ablative radiation (SAbR) for oligometastatic kidney cancer","volume":"39","author":"Hannan","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.03.009_b0135","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3109\/0284186X.2014.939298","article-title":"Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review","volume":"54","author":"Kothari","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.euo.2025.03.009_b0140","first-page":"454","article-title":"An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma","volume":"72","author":"Hasanov","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2025.03.009_b0145","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-018-0055-y","article-title":"Brain metastases","volume":"5","author":"Achrol","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.euo.2025.03.009_b0155","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.euo.2018.08.028","article-title":"Surgical metastasectomy in renal cell carcinoma: a systematic review","volume":"2","author":"Ouzaid","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.03.009_b0160","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1803675","article-title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","volume":"379","author":"M\u00e9jean","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.03.009_b0165","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamaoncol.2018.5543","article-title":"Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial","volume":"5","author":"Bex","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2025.03.009_b0170","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(16)30196-6","article-title":"Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial","volume":"17","author":"Rini","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.03.009_b0175","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.12968\/bjon.2021.30.10.S30","article-title":"The psychological impact of active surveillance in men with prostate cancer: Implications for nursing care","volume":"30","author":"Biddle","year":"2021","journal-title":"Br J Nurs"},{"key":"10.1016\/j.euo.2025.03.009_b0180","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.juro.2018.06.013","article-title":"Long-term cancer specific anxiety in men undergoing active surveillance of prostate cancer: findings from a large prospective cohort","volume":"200","author":"Marzouk","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.03.009_b0185","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41391-020-00279-z","article-title":"The association of cancer-specific anxiety with disease aggressiveness in men on active surveillance of prostate cancer","volume":"24","author":"Naha","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2025.03.009_b0190","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/j.juro.2009.12.099","article-title":"Do anxiety and distress increase during active surveillance for low risk prostate cancer?","volume":"183","author":"van den Bergh","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.03.009_b0195","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/eva.12020","article-title":"The effect of one additional driver mutation on tumor progression","volume":"6","author":"Reiter","year":"2013","journal-title":"Evol Appl"},{"key":"10.1016\/j.euo.2025.03.009_b0200","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.tpb.2010.05.001","article-title":"Evolutionary dynamics of tumor progression with random fitness values","volume":"78","author":"Durrett","year":"2010","journal-title":"Theor Popul Biol"},{"key":"10.1016\/j.euo.2025.03.009_b0205","doi-asserted-by":"crossref","first-page":"39511","DOI":"10.1038\/srep39511","article-title":"An exactly solvable, spatial model of mutation accumulation in cancer","volume":"6","author":"Paterson","year":"2016","journal-title":"Sci Rep."},{"key":"10.1016\/j.euo.2025.03.009_b0210","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.03.009_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjsurg.2024.116152","article-title":"The critical role of tumor size in predicting lymph node metastasis in early-stage colorectal cancer","volume":"241","author":"Ulkucu","year":"2025","journal-title":"Am J Surg"},{"key":"10.1016\/j.euo.2025.03.009_b0220","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.juro.2007.01.029","article-title":"Tumor size predicts synchronous metastatic renal cell carcinoma: implications for surveillance of small renal masses","volume":"177","author":"Kunkle","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.03.009_b0225","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.juro.2009.02.128","article-title":"Metastatic renal cell carcinoma risk according to tumor size","volume":"182","author":"Thompson","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.03.009_b0230","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1158\/0008-5472.CAN-12-4355","article-title":"The model muddle: In search of tumor growth laws","volume":"73","author":"Gerlee","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.euo.2025.03.009_b0235","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.03.009_b0240","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1200\/JCO.2003.02.122","article-title":"Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer","volume":"21","author":"Yang","year":"2003","journal-title":"J Clin Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125000847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125000847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T17:33:47Z","timestamp":1766511227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125000847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2588931125000847"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.03.009","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive Factors for Oligometastatic Renal Cell Carcinoma Treated with Stereotactic Radiation: A Retrospective Study","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}